CN101466364A - 鼻内施用氯胺酮治疗抑郁症 - Google Patents
鼻内施用氯胺酮治疗抑郁症 Download PDFInfo
- Publication number
- CN101466364A CN101466364A CNA2007800191257A CN200780019125A CN101466364A CN 101466364 A CN101466364 A CN 101466364A CN A2007800191257 A CNA2007800191257 A CN A2007800191257A CN 200780019125 A CN200780019125 A CN 200780019125A CN 101466364 A CN101466364 A CN 101466364A
- Authority
- CN
- China
- Prior art keywords
- ketamine
- depression
- antidepressant
- administration
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
Description
Claims (31)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78510806P | 2006-03-22 | 2006-03-22 | |
US60/785,108 | 2006-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101466364A true CN101466364A (zh) | 2009-06-24 |
Family
ID=38541630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800191257A Pending CN101466364A (zh) | 2006-03-22 | 2007-03-20 | 鼻内施用氯胺酮治疗抑郁症 |
Country Status (8)
Country | Link |
---|---|
US (6) | US8785500B2 (zh) |
EP (1) | EP2012762A4 (zh) |
JP (1) | JP2009530385A (zh) |
KR (1) | KR20090029690A (zh) |
CN (1) | CN101466364A (zh) |
AU (1) | AU2007229866A1 (zh) |
IL (1) | IL194198A0 (zh) |
WO (1) | WO2007111880A2 (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104519878A (zh) * | 2012-03-12 | 2015-04-15 | 詹森药业有限公司 | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 |
CN105073096A (zh) * | 2013-03-15 | 2015-11-18 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
CN105377371A (zh) * | 2013-04-12 | 2016-03-02 | 西奈山伊坎医学院 | 创伤后应激障碍的治疗方法 |
CN106562952A (zh) * | 2015-10-09 | 2017-04-19 | 北京安珀科技有限责任公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
CN107735081A (zh) * | 2015-05-20 | 2018-02-23 | 詹森药业有限公司 | 用于治疗抑郁症的方法和药盒 |
CN107847469A (zh) * | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
CN108853504A (zh) * | 2017-05-09 | 2018-11-23 | 浙江大学 | T型钙离子通道抑制剂对抑郁症的调节和用途 |
CN108853502A (zh) * | 2017-05-09 | 2018-11-23 | 浙江大学 | 治疗抑郁症的方法和药物组合物 |
CN108853510A (zh) * | 2017-05-09 | 2018-11-23 | 浙江大学 | Nmdar抑制剂和t型钙离子通道抑制剂的组合对抑郁症的治疗和药物 |
TWI648049B (zh) * | 2016-05-25 | 2019-01-21 | National Health Research Institutes | 用於減低k他命之致精神病狀副作用及成癮疾患的方法與組成物 |
CN109793725A (zh) * | 2011-10-14 | 2019-05-24 | 美国政府健康及人类服务部 | 治疗忧郁症和神经性疼痛的药物组合物及其应用 |
CN111818912A (zh) * | 2017-12-29 | 2020-10-23 | 赛隆制药股份公司 | 用于通过肺部给药而治疗抑郁症的干粉氯胺酮组合物 |
CN112702995A (zh) * | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
US11173134B2 (en) | 2014-09-15 | 2021-11-16 | Janssen Pharmaceutica Nv | Methods for the treatment of depression |
CN114126595A (zh) * | 2019-03-05 | 2022-03-01 | 杨森制药公司 | 用于治疗抑郁症的艾司氯胺酮 |
CN114306219A (zh) * | 2020-09-30 | 2022-04-12 | 四川普锐特药业有限公司 | 稳定的r-氯胺酮药物组合物 |
CN115135317A (zh) * | 2020-01-22 | 2022-09-30 | 西洛斯治疗有限公司 | 减少nmda拮抗剂的副作用 |
US11707440B2 (en) | 2017-12-22 | 2023-07-25 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
WO2023207730A1 (zh) * | 2022-04-26 | 2023-11-02 | 宜昌人福药业有限责任公司 | R-氯胺酮液体制剂及其用途 |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247946B2 (en) | 2004-06-14 | 2012-08-21 | Massachusetts Institute Of Technology | Electrochemical actuator |
US7999435B2 (en) | 2004-06-14 | 2011-08-16 | Massachusetts Institute Of Technology | Electrochemical actuator |
US7994686B2 (en) | 2004-06-14 | 2011-08-09 | Massachusetts Institute Of Technology | Electrochemical methods, devices, and structures |
WO2005124918A2 (en) | 2004-06-14 | 2005-12-29 | Massachusetts Institute Of Technology | Electrochemical actuating methods, devices and structures |
US7872396B2 (en) | 2004-06-14 | 2011-01-18 | Massachusetts Institute Of Technology | Electrochemical actuator |
KR20090029690A (ko) * | 2006-03-22 | 2009-03-23 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 우울증을 치료하기 위한 케타민의 투여 방법 |
WO2009015389A2 (en) * | 2007-07-26 | 2009-01-29 | Entra Pharmaceuticals Inc. | Skin-patch pump comprising a changing-volume electrochemical actuator |
EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
US8337457B2 (en) | 2010-05-05 | 2012-12-25 | Springleaf Therapeutics, Inc. | Systems and methods for delivering a therapeutic agent |
EP2652324A2 (en) | 2010-12-17 | 2013-10-23 | Massachusetts Institute Of Technology | Electrochemical actuators |
US9073819B2 (en) | 2011-06-30 | 2015-07-07 | University Of South Florida | Compositions, methods of use, and methods of treatment |
AU2013201492A1 (en) * | 2012-03-13 | 2013-10-03 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
JP2015512418A (ja) * | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
JP6722453B2 (ja) * | 2012-08-23 | 2020-07-15 | スチュアート エル ウェグ | 抗不安薬組成物、製剤および使用方法 |
US8974365B2 (en) * | 2012-11-25 | 2015-03-10 | Steven Richard Devore Best | Treatment of thalamocortical dysrhythmia |
ES2745024T3 (es) * | 2013-03-15 | 2020-02-27 | Janssen Pharmaceutica Nv | Composición farmacéutica de clorhidrato de S-ketamina |
WO2014186400A1 (en) | 2013-05-13 | 2014-11-20 | Icahn School Of Medicine At Mount Sinai | Treatment of mood and anxiety disorders |
RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
WO2015108985A1 (en) * | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
US11207316B2 (en) | 2014-05-30 | 2021-12-28 | West Virginia University | Ketamine or dextromethorphan formulations and methods of use |
WO2016025581A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
EP4227954A1 (en) | 2014-09-23 | 2023-08-16 | Icahn School of Medicine at Mount Sinai | Systems and methods for treating a psychiatric disorder |
EP3240422A1 (en) * | 2014-12-31 | 2017-11-08 | Icahn School of Medicine at Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
WO2016172672A1 (en) * | 2015-04-24 | 2016-10-27 | Icahn School Of Medicine At Mount Sinai | Method for treating suicidal ideation |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
WO2017041112A1 (en) * | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTIC AGENTS AGAINST STRESS INDUCED DISORDERS AND ASSOCIATED SYMPTOMS |
IL264908B2 (en) | 2016-08-25 | 2023-09-01 | Validose Inc | A system and method for controlled medical treatment |
US9963435B2 (en) | 2016-08-31 | 2018-05-08 | Dart Neuroscience, Llc | Compounds for therapeutic use |
EP3548014A4 (en) | 2016-11-30 | 2020-07-29 | Philip E. Wolfson | KETAMINE FOR TREATING SYMPTOMS RELATED TO MENSTRUATION |
EP3636281B1 (en) * | 2017-05-09 | 2023-11-01 | Zhejiang University | Method for treating depression, and pharmaceutical composition |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
CA3082423A1 (en) * | 2017-11-14 | 2019-05-23 | Bexson Biomedical, Inc. | Systems, devices, formulations and methods for controlled drug delivery |
EP3768378A4 (en) | 2018-03-22 | 2021-11-17 | InCarda Therapeutics, Inc. | INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE |
EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | DRUG TREATMENT METHODS |
US11154537B2 (en) | 2018-08-10 | 2021-10-26 | Eleusis Therapeutics Us, Inc. | Method of treatment for ketamine infusion |
US10555917B1 (en) * | 2018-08-16 | 2020-02-11 | BNIW Ventures LLC. | Methods of treating a neurological or psychiatric disorder |
WO2020041329A1 (en) * | 2018-08-20 | 2020-02-27 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
EP3628313A1 (en) * | 2018-09-28 | 2020-04-01 | Celon Pharma S.A. | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
GB2594616A (en) * | 2018-11-21 | 2021-11-03 | Certego Therapeutics Inc | Gaboxadol for reducing risk of suicide and rapid relief of depression |
EP3955918A1 (en) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
WO2020232246A1 (en) * | 2019-05-15 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Compositions and methods against stress-induced affective disorders and their associated symptoms |
EP3968979A4 (en) | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
KR20220016484A (ko) | 2019-05-31 | 2022-02-09 | 셀론 파르마 에스.에이. | 약학적 조성물의 전자적으로 관리된 비경구 투여용 흡입기 |
JP2022542746A (ja) | 2019-05-31 | 2022-10-07 | セロン ファーマ エス.アー. | 医薬組成物の電子的に監督された投与 |
JP2022535920A (ja) * | 2019-06-07 | 2022-08-10 | パックスメディカ, インコーポレイテッド | 中枢神経系障害を処置するための組成物および方法 |
CA3142934A1 (en) | 2019-06-09 | 2020-12-17 | Kblv Medical, Llc | Device and system for remote regulation and monitoring of drug delivery and method of same |
US20220304980A1 (en) * | 2019-07-04 | 2022-09-29 | SW Holdings, Inc | Metered dosing compositions and methods of use of psychedelic compounds |
US20220347123A1 (en) * | 2019-10-02 | 2022-11-03 | Praxis Precision Medicines, Inc. | Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists |
CA3156658A1 (en) | 2019-10-18 | 2021-04-22 | Institute Of Science And Technology Austria | NEURONAL PLASTICITY STIMULATION |
US20230066347A1 (en) * | 2020-05-15 | 2023-03-02 | University Of Kansas | Ketamine treatment for amyotrophic lateral sclerosis |
EP4153549A2 (en) | 2020-05-20 | 2023-03-29 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
EP4247340A1 (en) | 2020-11-18 | 2023-09-27 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds |
TW202310825A (zh) * | 2021-05-14 | 2023-03-16 | 美商西羅斯醫療公司 | 減少nmda受體拮抗劑之副作用 |
WO2022241214A1 (en) * | 2021-05-14 | 2022-11-17 | Seelos Therapeutics, Inc. | Methods of using nmda receptor antagonists |
EP4351568A1 (en) * | 2021-05-26 | 2024-04-17 | Mindset Pharma Inc. | Hallucinogen-fatty acid combination |
US20240065989A1 (en) * | 2022-08-31 | 2024-02-29 | Zyvran Pharmaceuticals | Method and composition for treating treatment resistant depression |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
EP1551393A4 (en) * | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
KR20090029690A (ko) * | 2006-03-22 | 2009-03-23 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 우울증을 치료하기 위한 케타민의 투여 방법 |
-
2007
- 2007-03-20 KR KR1020087025793A patent/KR20090029690A/ko not_active Application Discontinuation
- 2007-03-20 WO PCT/US2007/006898 patent/WO2007111880A2/en active Application Filing
- 2007-03-20 JP JP2009501506A patent/JP2009530385A/ja not_active Withdrawn
- 2007-03-20 EP EP07753520A patent/EP2012762A4/en not_active Withdrawn
- 2007-03-20 AU AU2007229866A patent/AU2007229866A1/en not_active Abandoned
- 2007-03-20 US US11/688,603 patent/US8785500B2/en active Active
- 2007-03-20 CN CNA2007800191257A patent/CN101466364A/zh active Pending
-
2008
- 2008-09-18 IL IL194198A patent/IL194198A0/en unknown
-
2014
- 2014-03-05 US US14/197,767 patent/US9539220B2/en active Active
- 2014-06-17 US US14/306,382 patent/US9592207B2/en active Active
-
2016
- 2016-12-14 US US15/379,013 patent/US20170151191A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/417,689 patent/US20170181966A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,090 patent/US20200253894A1/en not_active Abandoned
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109793725A (zh) * | 2011-10-14 | 2019-05-24 | 美国政府健康及人类服务部 | 治疗忧郁症和神经性疼痛的药物组合物及其应用 |
CN109793725B (zh) * | 2011-10-14 | 2023-07-25 | 美国政府健康及人类服务部 | 治疗忧郁症和神经性疼痛的药物组合物及其应用 |
CN104519878A (zh) * | 2012-03-12 | 2015-04-15 | 詹森药业有限公司 | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 |
CN105073096A (zh) * | 2013-03-15 | 2015-11-18 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
CN111643449A (zh) * | 2013-03-15 | 2020-09-11 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
CN105377371A (zh) * | 2013-04-12 | 2016-03-02 | 西奈山伊坎医学院 | 创伤后应激障碍的治疗方法 |
US11771661B2 (en) | 2013-04-12 | 2023-10-03 | Icahn School Of Medicine At Mount Sinai | Method of treating post-traumatic stress disorder |
US10478405B2 (en) | 2013-04-12 | 2019-11-19 | Icahn School Of Medicine At Mount Sinai | Method for treating post-traumatic stress disorder |
US11311500B2 (en) | 2014-09-15 | 2022-04-26 | Janssen Pharmaceutica Nv | Methods for the treatment of depression |
US11173134B2 (en) | 2014-09-15 | 2021-11-16 | Janssen Pharmaceutica Nv | Methods for the treatment of depression |
CN107735081A (zh) * | 2015-05-20 | 2018-02-23 | 詹森药业有限公司 | 用于治疗抑郁症的方法和药盒 |
CN107847469A (zh) * | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
CN106562952A (zh) * | 2015-10-09 | 2017-04-19 | 北京安珀科技有限责任公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
TWI648049B (zh) * | 2016-05-25 | 2019-01-21 | National Health Research Institutes | 用於減低k他命之致精神病狀副作用及成癮疾患的方法與組成物 |
CN108853510A (zh) * | 2017-05-09 | 2018-11-23 | 浙江大学 | Nmdar抑制剂和t型钙离子通道抑制剂的组合对抑郁症的治疗和药物 |
CN108853504A (zh) * | 2017-05-09 | 2018-11-23 | 浙江大学 | T型钙离子通道抑制剂对抑郁症的调节和用途 |
CN108853502A (zh) * | 2017-05-09 | 2018-11-23 | 浙江大学 | 治疗抑郁症的方法和药物组合物 |
CN115025224A (zh) * | 2017-05-09 | 2022-09-09 | 浙江大学 | T型钙离子通道抑制剂治疗抑郁症的方法和药物 |
CN115025227A (zh) * | 2017-05-09 | 2022-09-09 | 浙江大学 | 联合用药治疗抑郁症的方法和药物组合物 |
CN108853510B (zh) * | 2017-05-09 | 2022-05-20 | 浙江大学 | Nmdar抑制剂和t型钙离子通道抑制剂的组合对抑郁症的治疗和药物 |
CN108853504B (zh) * | 2017-05-09 | 2022-05-20 | 浙江大学 | T型钙离子通道抑制剂对抑郁症的调节和用途 |
US11707440B2 (en) | 2017-12-22 | 2023-07-25 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
CN111818912A (zh) * | 2017-12-29 | 2020-10-23 | 赛隆制药股份公司 | 用于通过肺部给药而治疗抑郁症的干粉氯胺酮组合物 |
CN112702995A (zh) * | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
US11865088B2 (en) | 2018-10-05 | 2024-01-09 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
US11957645B2 (en) | 2018-10-05 | 2024-04-16 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
CN114126595A (zh) * | 2019-03-05 | 2022-03-01 | 杨森制药公司 | 用于治疗抑郁症的艾司氯胺酮 |
US11883526B2 (en) | 2019-03-05 | 2024-01-30 | Janssen Pharmaceutica Nv | Esketamine for the treatment of depression |
CN115135317A (zh) * | 2020-01-22 | 2022-09-30 | 西洛斯治疗有限公司 | 减少nmda拮抗剂的副作用 |
CN114306219A (zh) * | 2020-09-30 | 2022-04-12 | 四川普锐特药业有限公司 | 稳定的r-氯胺酮药物组合物 |
CN114306219B (zh) * | 2020-09-30 | 2023-09-26 | 四川普锐特药业有限公司 | 稳定的r-氯胺酮药物组合物 |
WO2023207730A1 (zh) * | 2022-04-26 | 2023-11-02 | 宜昌人福药业有限责任公司 | R-氯胺酮液体制剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2007111880A9 (en) | 2007-11-29 |
WO2007111880A2 (en) | 2007-10-04 |
US9539220B2 (en) | 2017-01-10 |
AU2007229866A1 (en) | 2007-10-04 |
EP2012762A2 (en) | 2009-01-14 |
WO2007111880A3 (en) | 2008-01-17 |
US20170181966A1 (en) | 2017-06-29 |
US20170151191A1 (en) | 2017-06-01 |
US8785500B2 (en) | 2014-07-22 |
KR20090029690A (ko) | 2009-03-23 |
EP2012762A4 (en) | 2010-03-10 |
US20200253894A1 (en) | 2020-08-13 |
US9592207B2 (en) | 2017-03-14 |
JP2009530385A (ja) | 2009-08-27 |
US20140256821A1 (en) | 2014-09-11 |
US20150056308A1 (en) | 2015-02-26 |
IL194198A0 (en) | 2009-08-03 |
US20070287753A1 (en) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200253894A1 (en) | Intranasal administration of ketamine to treat depression | |
US20220387306A1 (en) | Compositions and methods for the treatment of opioid overdose | |
US9629965B2 (en) | Nasal drug products and methods of their use | |
US9211253B2 (en) | Nasal drug products and methods of their use | |
KR102424765B1 (ko) | 외상후 스트레스 장애의 치료 방법 | |
US20220249605A1 (en) | Treatment of Mood and Anxiety Disorders | |
CN112423789A (zh) | 用于治疗抑郁症的艾司氯胺酮 | |
JP2019520361A (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
JP2022546456A (ja) | 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン | |
Bitter | Transmucosal nasal drug delivery: pharmacokinetics and pharmacodynamics of nasally applied esketamine | |
Aan het Rot et al. | Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder. | |
EA046262B1 (ru) | Уменьшение побочных эффектов антагонистов n-метил-d-аспартата (nmda) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Applicant Correct: Mount Sinai School of medicine New York University False: Sinai School Medicine,univ New York Number: 25 Page: 1182 Volume: 25 |
|
CI02 | Correction of invention patent application |
Correction item: Applicant Correct: Mount Sinai School of medicine New York University False: Sinai School Medicine,univ New York Number: 25 Page: The title page Volume: 25 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1132185 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090624 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1132185 Country of ref document: HK |